October 2019 - Volume 29 - Issue 5 - Contributor Index

Alphabetical Search
U
X
Y

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status

Komina, Anna V.; Palkina, Nadezhda V.; Aksenenko, Mariya B.; More

Melanoma Research. 29(5):544-548, October 2019.

Author:
Allayous, Clara
Author:
Allez, Matthieu
Author:
Andruska, Neal

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status

Komina, Anna V.; Palkina, Nadezhda V.; Aksenenko, Mariya B.; More

Melanoma Research. 29(5):544-548, October 2019.

Author:
Ballon, Alice
Author:
Basile, Debora

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

Johansson, Peter A.; Nathan, Vaishnavi; Bourke, Lauren M.; More

Melanoma Research. 29(5):483-490, October 2019.

Author:
Brown, Kevin M.

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

Johansson, Peter A.; Nathan, Vaishnavi; Bourke, Lauren M.; More

Melanoma Research. 29(5):483-490, October 2019.

Author:
Brungs, Daniel

Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy

Duggan, Megan C.; Regan-Fendt, Kelly; Olaverria Salavaggione, Gonzalo N.; More

Melanoma Research. 29(5):491-500, October 2019.

Author:
Cebon, Jonathan

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Author:
Chang, Sung E.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Author:
Choi, Jee H.
Author:
Dalland, Lindi

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy

Duggan, Megan C.; Regan-Fendt, Kelly; Olaverria Salavaggione, Gonzalo N.; More

Melanoma Research. 29(5):491-500, October 2019.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Author:
Delyon, Julie

Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy

Duggan, Megan C.; Regan-Fendt, Kelly; Olaverria Salavaggione, Gonzalo N.; More

Melanoma Research. 29(5):491-500, October 2019.

Author:
Duong, Tuan Anh

Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy

Duggan, Megan C.; Regan-Fendt, Kelly; Olaverria Salavaggione, Gonzalo N.; More

Melanoma Research. 29(5):491-500, October 2019.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

Johansson, Peter A.; Nathan, Vaishnavi; Bourke, Lauren M.; More

Melanoma Research. 29(5):483-490, October 2019.

Author:
Gonzalez, Rene
Author:
Gru, Alejandro

Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy

Duggan, Megan C.; Regan-Fendt, Kelly; Olaverria Salavaggione, Gonzalo N.; More

Melanoma Research. 29(5):491-500, October 2019.

Author:
Haggstrom, Lucy

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

Johansson, Peter A.; Nathan, Vaishnavi; Bourke, Lauren M.; More

Melanoma Research. 29(5):483-490, October 2019.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

Johansson, Peter A.; Nathan, Vaishnavi; Bourke, Lauren M.; More

Melanoma Research. 29(5):483-490, October 2019.

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

Johansson, Peter A.; Nathan, Vaishnavi; Bourke, Lauren M.; More

Melanoma Research. 29(5):483-490, October 2019.

Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy

Duggan, Megan C.; Regan-Fendt, Kelly; Olaverria Salavaggione, Gonzalo N.; More

Melanoma Research. 29(5):491-500, October 2019.

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

Johansson, Peter A.; Nathan, Vaishnavi; Bourke, Lauren M.; More

Melanoma Research. 29(5):483-490, October 2019.

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

Johansson, Peter A.; Nathan, Vaishnavi; Bourke, Lauren M.; More

Melanoma Research. 29(5):483-490, October 2019.

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

Johansson, Peter A.; Nathan, Vaishnavi; Bourke, Lauren M.; More

Melanoma Research. 29(5):483-490, October 2019.

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

Johansson, Peter A.; Nathan, Vaishnavi; Bourke, Lauren M.; More

Melanoma Research. 29(5):483-490, October 2019.

Author:
Kim, Hak T.
Author:
Komina, Anna V.

Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status

Komina, Anna V.; Palkina, Nadezhda V.; Aksenenko, Mariya B.; More

Melanoma Research. 29(5):544-548, October 2019.

Author:
Langan, Ewan A.

Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy

Duggan, Megan C.; Regan-Fendt, Kelly; Olaverria Salavaggione, Gonzalo N.; More

Melanoma Research. 29(5):491-500, October 2019.

Author:
Lau, Mike

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status

Komina, Anna V.; Palkina, Nadezhda V.; Aksenenko, Mariya B.; More

Melanoma Research. 29(5):544-548, October 2019.

Author:
Lee, Mi H.
Author:
Lee, Mi W.
Author:
Lee, Woo J.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Author:
Lenz, Guido
Author:
Linardou, Helen

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Author:
Mackin, Anna G.
Author:
Mahapatra, Lily
Author:
Mann, Graham

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

Johansson, Peter A.; Nathan, Vaishnavi; Bourke, Lauren M.; More

Melanoma Research. 29(5):483-490, October 2019.

Author:
Mao, Chengjian

Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy

Duggan, Megan C.; Regan-Fendt, Kelly; Olaverria Salavaggione, Gonzalo N.; More

Melanoma Research. 29(5):491-500, October 2019.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600–mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; More

Melanoma Research. 29(5):527-532, October 2019.

Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status

Komina, Anna V.; Palkina, Nadezhda V.; Aksenenko, Mariya B.; More

Melanoma Research. 29(5):544-548, October 2019.

Author:
Mourad, Nadim

Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

Johansson, Peter A.; Nathan, Vaishnavi; Bourke, Lauren M.; More

Melanoma Research. 29(5):483-490, October 2019.